Evidence map›Paper›PMID 29216385›Full record

ArticleNeuro-oncology2018

De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Matthieu Peyre, Guillaume Gauchotte, Marine Giry, Sébastien Froehlich, Johan Pallud, Thomas Graillon, Franck Bielle, Dominique Cazals-Hatem, Pascale Varlet, Dominique Figarella-Branger and 2 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Matthieu PeyreDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
Guillaume GauchotteDepartment of Pathology, CHRU, INSERM U954, Nancy, France.
Marine GiryInserm 1127 Unit-Institut du Cerveau et de la Moelle Epinière, Paris, France.
Sébastien FroehlichDepartment of Neurosurgery, Hôpital Lariboisière, APHP, Paris, France.
Johan PalludDepartment of Neurosurgery, Hôpital Sainte-Anne, Paris, France.
Thomas GraillonDepartment of Neurosurgery, Hôpital la Timone, Marseille, France.
Franck BielleDepartment of Neuropathology, Hopital Pitié-Salpêtrière, APHP, Paris, France.
Dominique Cazals-HatemDepartment of Neuropathology, Hôpital Beaujon, Clichy, France.
Pascale VarletParis Descartes University, Sorbonne Paris Cité, Paris, France.
Dominique Figarella-BrangerAix-Marseille Univ, APHM, INSERM, CRO2, La Timone Hospital, Department of Pathology and Neuropathology, Marseille, France.
Hugues LoiseauDepartment of Neurosurgery, Hopital Pellegrin, Bordeaux, France.
Michel KalamaridesDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
Inserm · FRDélégation Paris 5 · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Beaujon · FRHôpital de la Timone · FRHôpital Pellegrin · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Following recent studies underlining the differences between de novo and secondary anaplastic meningiomas and the prognostic value of telomerase reverse transcriptase (TERT) promoter mutation, we decided to conduct a multicenter retrospective study to address these questions and determine specific prognostic factors in each of these 2 anaplastic meningioma subgroups. Methods: Among the 68 meningioma cases initially selected, only 57 were confirmed as anaplastic meningiomas after centralized pathological review. TERT promoter mutation analysis was performed in all cases. Results: Median overall survival was 2.6 years and 5-year survival rate was 10%. This study confirmed the better prognosis of de novo anaplastic meningiomas (28 tumors) compared with secondary anaplastic meningiomas (29 tumors) (P = 0.02). In the "de novo" group, meningiomas diagnosed on histological anaplasia alone had a better prognosis than those in patients with a high number of mitoses with or without anaplasia (P = 0.01). In the "secondary" group, tumors demonstrate very heterogeneous clinical courses leading to malignant transformation, and time to first relapse as a low-grade tumor was a strong predictor of overall survival (P = 0.0007). TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02). The absence of TERT promoter methylation, although rare (3/33 cases), may be associated with prolonged overall survival (P = 0.02). Conclusion: This study highlights the different prognoses of de novo and secondary anaplastic meningiomas with specific prognostic factors in each subgroup. The analysis of TERT mutation and methylation could provide additional prognostic insights.

Indexed as

MutationAdultAgedAged, 80 and overCarcinomaDisease ProgressionDNA MethylationFemaleFollow-Up StudiesHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeoplasm Recurrence, LocalPrognosisTelomeraseTERT protein, human

Identifiers

PMID29216385
PMCPMC6280137
OpenAlexW2774593410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.